RECRUITING

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Description

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

Study Overview

Study Details

Study overview

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Condition
Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Houston

SPARC Investigative Site, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Willing and able to give written and dated informed consent (or legally acceptable representative/ impartial witness when applicable) and is available for the entire study.
  • 2. Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions (in the Investigator's opinion), and be accessible for follow-up.
  • 3. Has locally recurrent or metastatic disease (except sarcomas) which has relapsed or progressed following local standard treatment, or for which no standard treatment is available.
  • 4. Has a life expectancy of ≥3 months.
  • 1. Any major surgery, as determined by the Investigator, within 4 weeks of SBO-154 administration.
  • 2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination.
  • 3. Known or suspected history of significant drug abuse as judged by the Investigator.
  • 4. Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  • 5. Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry.
  • 6. Positive exclusion tests: urine pregnancy tests (if applicable), serology tests positive for HIV, HCV, HBsAg (unless they are considered subjects with resolved Hepatitis B and C infection).
  • 7. History of any relevant allergy/ hypersensitivity including known immediate or delayed hypersensitivity reaction or idiosyncrasy to biological agents or drug chemically related to SBO-154 or its excipients.
  • 8. Received an investigational agent within 30 days or 5 half-lives- whichever is shorter prior to SBO-154 administration.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sun Pharma Advanced Research Company Limited,

Study Record Dates

2030-08